| A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules (NCT06306872) | Abbisko Therapeutics Co, Ltd | 2024-02-23 |
| Bioavailability Study of Fexofenadine HCl New Formulation Tablet (NCT06284902) | Opella Healthcare Group SAS, a Sanofi Company | 2024-02-23 |
| Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer (NCT06312423) | Ministry of Public Health of the Province of La Rioja | 2024-02-23 |
| Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) (NCT05986864) | Skyline Therapeutics (US) Inc. | 2024-02-23 |
| COES: Curing Order Effects on Sealants (NCT06342258) | University of Southern California | 2024-02-23 |
| A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) (NCT06287528) | Memorial Sloan Kettering Cancer Center | 2024-02-23 |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients (NCT06071013) | China Medical University Hospital | 2024-02-23 |
| A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant (NCT06275841) | Pfizer | 2024-02-23 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors (NCT06264921) | NiKang Therapeutics, Inc. | 2024-02-23 |
| CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML (NCT05945849) | University of Pennsylvania | 2024-02-23 |
| Phase I Study of RiMO-401 With Radiation in Advanced Tumors (NCT06182579) | Coordination Pharmaceuticals, Inc. | 2024-02-22 |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06121843) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-02-22 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer (NCT06225804) | Abbisko Therapeutics Co, Ltd | 2024-02-22 |
| Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer (NCT07334431) | Henan Cancer Hospital | 2024-02-22 |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT06001788) | Kura Oncology, Inc. | 2024-02-22 |
| A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. (NCT06232096) | Beijing Mabworks Biotech Co., Ltd. | 2024-02-22 |
| Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects (NCT06232109) | Asceneuron S.A. | 2024-02-22 |
| Use of Phage Therapy for Treatment of a Periprosthetic Joint Infection (NCT06827041) | Ottawa Hospital Research Institute | 2024-02-22 |
| A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration (NCT06278766) | AbbVie | 2024-02-21 |
| Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects (NCT06126718) | BioRay Pharmaceutical Co., Ltd. | 2024-02-21 |
| Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant (NCT06372483) | VarmX B.V. | 2024-02-21 |
| Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (NCT06071624) | Huda Salman | 2024-02-21 |
| Behavioral Exercise Training to Reduce Cardiovascular Disease Risk (NCT06237179) | Virginia Commonwealth University | 2024-02-21 |
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation (NCT06706388) | n-Lorem Foundation | 2024-02-21 |
| Effect of Intraarticular Injection of Tenoxicam and Hyaluronic Acid Versus Platelet-Rich Plasma and Hyaluronic Acid in Temporomandibular Joint Internal Derangement (NCT06572904) | Mansoura University | 2024-02-20 |
| SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation (NCT06222580) | Uma Borate | 2024-02-20 |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (NCT06215118) | Pfizer | 2024-02-20 |
| Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (NCT06343038) | University Hospital, Basel, Switzerland | 2024-02-20 |
| Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults (NCT05978908) | Neurodegenerative Disease Research Inc | 2024-02-20 |
| Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (NCT06227026) | University of Utah | 2024-02-20 |
| A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons (NCT06298032) | Ferring Pharmaceuticals | 2024-02-20 |
| JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure (NCT05998408) | National Heart, Lung, and Blood Institute (NHLBI) | 2024-02-20 |
| Single and Multiple Ascending Dose Study and Food Effect Study for AG181 (NCT06286033) | Agios Pharmaceuticals, Inc. | 2024-02-20 |
| Effect of Quercetin in Treatment of Periodontitis (NCT05928546) | Assiut University | 2024-02-20 |
| GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors (NCT06265025) | GeneMedicine Co., Ltd. | 2024-02-20 |
| CIML NK Cells With Venetoclax for AML (NCT06152809) | Dana-Farber Cancer Institute | 2024-02-20 |
| A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma (NCT05736406) | Hemerion Therapeutics | 2024-02-20 |
| A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus (NCT06279234) | Pfizer | 2024-02-20 |
| A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (NCT06185764) | Vertex Pharmaceuticals Incorporated | 2024-02-20 |
| Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (NCT06222879) | Shandong Suncadia Medicine Co., Ltd. | 2024-02-20 |
| Pilot Study of MC in Paediatric Palliative Care (NCT05615389) | Murdoch Childrens Research Institute | 2024-02-19 |
| A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (NCT06206837) | Pfizer | 2024-02-19 |
| A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM) (NCT07065032) | Beijing QL Biopharmaceutical Co.,Ltd | 2024-02-19 |
| A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects (NCT06277492) | GEN İlaç ve Sağlık Ürünleri A.Ş. | 2024-02-19 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (NCT05993611) | City of Hope Medical Center | 2024-02-19 |
| A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies (NCT06388902) | BioRay Pharmaceutical Co., Ltd. | 2024-02-19 |
| A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) (NCT06239714) | Suzhou Sanegene Bio Inc. | 2024-02-18 |
| PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors (NCT06897228) | Shenzhen Celconta Life Science Co., Ltd. | 2024-02-18 |
| Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia (NCT06585345) | The General Hospital of Western Theater Command | 2024-02-18 |
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (NCT05756166) | Roswell Park Cancer Institute | 2024-02-16 |
| Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants (NCT06243770) | ModernaTX, Inc. | 2024-02-16 |
| An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604 (NCT06157255) | AstraZeneca | 2024-02-16 |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors (NCT06244485) | Daiichi Sankyo | 2024-02-16 |
| RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus (NCT06121297) | Cabaletta Bio | 2024-02-16 |
| A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (NCT06091930) | Boehringer Ingelheim | 2024-02-16 |
| Impact VR: An Emotion Recognition and Regulation Training Program for Youth With CD (NCT06301516) | Virginia Commonwealth University | 2024-02-16 |
| Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A (NCT06314490) | University of California, San Diego | 2024-02-16 |
| Biphasic Material With PRF in Lateral Sinus Floor Augmentation (NCT06071416) | Assiut University | 2024-02-15 |
| The Herbal Acupoint Patch for Dialysis Patient With Fistula-related Pain (NCT07380581) | Chang Gung Memorial Hospital | 2024-02-15 |
| A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (NCT05836896) | Technische Universität Dresden | 2024-02-15 |
| Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer (NCT06255262) | China Medical University, China | 2024-02-15 |
| Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab (NCT06272695) | REMD Biotherapeutics, Inc. | 2024-02-15 |
| Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis (NCT05145816) | University of Texas Southwestern Medical Center | 2024-02-15 |
| TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors (NCT06438783) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2024-02-15 |
| Cannabinoids for Pain Management and Neuroprotection From Concussion (NCT06204003) | University of Regina | 2024-02-15 |
| A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer (NCT06255964) | SUNHO（China）BioPharmaceutical CO., Ltd. | 2024-02-15 |
| A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) (NCT06153095) | Lyell Immunopharma, Inc. | 2024-02-15 |
| A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV (NCT06102174) | Pfizer | 2024-02-15 |
| A Study of How CagriSema Works on Appetite in People With Excess Body Weight (NCT06267092) | Novo Nordisk A/S | 2024-02-15 |
| Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® (NCT06298409) | Envivo Bio Inc | 2024-02-15 |
| A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (NCT06049082) | Krystal Biotech, Inc. | 2024-02-15 |
| A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants (NCT06268860) | Amgen | 2024-02-15 |
| LIONS (PLK4 Inhibitor in Advanced Solid Tumors) (NCT06232408) | Repare Therapeutics | 2024-02-14 |
| DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (NCT05990738) | Boehringer Ingelheim | 2024-02-14 |
| A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants (NCT06189508) | Hoffmann-La Roche | 2024-02-14 |
| Bicalutamide Therapy in Young Women With NAFLD and PCOS (NCT05979389) | University of California, San Francisco | 2024-02-14 |
| Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia (NCT04881240) | St. Jude Children's Research Hospital | 2024-02-14 |
| DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (NCT06077500) | Boehringer Ingelheim | 2024-02-14 |
| Comparison of Skeletal Effects of Herbst and Invisalign MA in Growing Patients With KLass II Malocclusion (NCT06409923) | Université Libre de Bruxelles | 2024-02-14 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2" (NCT06226727) | Boryung Pharmaceutical Co., Ltd | 2024-02-14 |
| An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease (NCT06177431) | Neurizon Therapeutics Limited | 2024-02-13 |
| Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors (NCT06234098) | Alyssum Therapeutics | 2024-02-13 |
| Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz® (NCT06233071) | Bio-innova Co., Ltd | 2024-02-13 |
| A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer (NCT06016270) | STCube, Inc. | 2024-02-13 |
| Sleep Health Enhancement in Midlife Adults (NCT06311500) | University of Kansas Medical Center | 2024-02-13 |
| LEMURS SSI: Evaluation of Behavioral Incentives (NCT06340841) | University of Vermont | 2024-02-12 |
| The Bioequivalence Study of Acyclovir 800 mg Tablet in Healthy Thai Volunteers Under Fasting Conditions (NCT06228430) | International Bio service | 2024-02-12 |
| Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants (NCT06206811) | Odyssey Therapeutics | 2024-02-12 |
| Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM) (NCT05525572) | University of Miami | 2024-02-12 |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (NCT06244771) | Frontier Medicines Corporation | 2024-02-12 |
| The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis (NCT06283589) | Inozyme Pharma | 2024-02-12 |
| A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants (NCT06264440) | Biogen | 2024-02-12 |
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). (NCT06159166) | Johns Hopkins University | 2024-02-12 |
| DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) (NCT06027086) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2024-02-12 |
| Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus (NCT06222853) | The Children's Hospital of Zhejiang University School of Medicine | 2024-02-10 |
| Noninvasive Modulation of Chronic Neuropathic Pain (NCT06249724) | University of Utah | 2024-02-10 |
| A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003) (NCT06692647) | Merck Sharp & Dohme LLC | 2024-02-09 |
| Bioavailability Clinical Trial of Oral Minoxidil 1 mg (NCT06015516) | Industrial Farmacéutica Cantabria, S.A. | 2024-02-09 |
| A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors (NCT06255665) | Janssen Research & Development, LLC | 2024-02-09 |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors (NCT06293898) | SystImmune Inc. | 2024-02-09 |